Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases

Posted on November 22, 2022

Bristol Myers Squibb (NYSE: BMY) announced the presentation of research across its hematology portfolio at the 64^th American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place in New Orleans, Louisiana, and virtually, from December 10 to 13, 2022. Data from more than 100 company-sponsored studies will be featured, including 34 oral presentations, highlighting the range of modalities, targets and research platforms the company is advancing and showcasing our commitment to scientific progress across hematologic diseases.

“Our presence at ASH underscores the transformational potential of our diverse pipeline, poised to deliver the next wave of advances in hematology,” said Samit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb. “These exciting data, spanning a variety of modalities and targets, demonstrate significant progress toward our goals of improving long-term outcomes across patient populations and finding solutions in important areas of remaining need.”

Key data being presented by Bristol Myers Squibb and its partners at the 2022 ASH Annual Meeting and Exposition include:

Cell Therapy

Updated data including longer-term follow up from the primary analysis of the Phase 3 TRANSFORM study evaluating Breyanzi^® (lisocabtagene maraleucel) versus the standard of care as a second-line treatment in relapsed or refractory large B-cell lymphoma (LBCL)
Updated data from the primary analysis of the Phase 2 OUTREACH study evaluating Breyanzi as a third-line plus treatment in relapsed or refractory LBCL in the community setting
Safety and efficacy results of the match-adjusted indirect comparison of the TRANSFORM versus ZUMA-7 studies evaluating Breyanzi versusaxicabtagene ciloleucelin the second-line setting in relapsed or refractory LBCL
Two first disclosures of results from cohorts 2a and 2c of the Phase 2 KarMMa-2 trial evaluating Abecma in high-risk multiple myeloma
First disclosure of preliminary Phase 1 results for GPRC5D chimeric antigen receptor (CAR) T cell therapy in patients with relapsed/refractory (R/R) multiple myeloma, including patients previously treated with a B-cell maturation antigen (BCMA)-directed CAR T cell therapy

Hematology

Multiple analyses of Reblozyl^®(luspatercept-aamt), including overall survival data from the Phase 3 MEDALIST study in lower-risk myelodysplastic syndromes and real-world, longer-term results from the Phase 2 BEYOND study in beta thalassemia
Multiple analyses of Inrebic^® (fedratinib), including the primary analysis of safety and efficacy from the Phase 3b FREEDOM trial in intermediate- or high-risk myelofibrosis
Longitudinal analyses of acute myeloid leukemia gene mutations with Onureg^® (azacitidine tablets) from the Phase 3 QUAZAR^® AML-001 study

Early Pipeline

First disclosure of preliminary results from the dose escalation and expansion components of the Phase 1 CC-93269 MM-001 study, evaluating subcutaneous bispecific T cell engager alnuctamab in heavily pretreated multiple myeloma
First results from dose expansion cohort of the CC-92480 Phase 1/2 MM-001 study, evaluating CELMoD^TM agent mezigdomide with dexamethasone in patients with R/R multiple myeloma
Results from post-BCMA cohort of the CC-220 Phase 1/2 MM-001 study, evaluating CELMoD agent iberdomide with dexamethasone in patients with R/R multiple myeloma previously treated with a BCMA-directed therapy
First results from a Phase 1/2 study evaluating BMS-986158, a potent Bromodomain and Extraterminal (BET) inhibitor, as monotherapy and in combination with ruxolitinib or Inrebic in intermediate- or high-risk myelofibrosis

Selected Bristol Myers Squibb studies at the 64^th ASH Annual Meeting and Exposition include:

Abstract Title	Author	Presentation Type/#	Session Title	Session Date/Time (CST)
*Beta Thalassemia*
Erythroid Response in Patients with Non-Transfusion-Dependent ß-Thalassemia Treated with Luspatercept: Long-Term Data from the BEYOND Trial	Ali Taher	Poster Presentation #3669	112. Thalassemia and Globin Gene Regulation: Poster III	Monday, December 12, 6:00 – 8:00 PM
*Lymphoma*
Five-Year Results From the Phase 3 Randomized Study AUGMENT: Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma	John Leonard	Oral Presentation #230	623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological III	Saturday, December 10, 2:15 PM
Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody as Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study	Catherine Thieblemont	Oral Presentation #233	623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological III	Saturday, December 10, 3:00 PM
Lisocabtagene Maraleucel (liso-cel) versus Standard of Care (SOC) with Salvage Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) as Second-line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 TRANSFORM Study	Jeremy Abramson	Oral Presentation #655	705. Cellular Immunotherapies: Results from CD19-Directed CAR T in treating Aggressive B-cell Lymphomas	Sunday, December 11, 4:30 PM
Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-line (2L) Treatment of Patients with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)	Jeremy Abramson	Poster Presentation #2031	705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I	Saturday December 10, 5:30 – 7:30 PM
Real-World Treatment Patterns and Costs of Chimeric Antigen Receptor (CAR) T Cell Therapies (CAR T), Polatuzumab Vedotin-piiq (pola), and Tafasitamab-cxix (tafa) in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)	Fei Fei Liu	Oral Presentation #999	905. Outcomes Research—Lymphoid Malignancies: Health Outcomes in CAR T and Stem Cell Transplantation	Monday, December 12, 5:00 PM
Results from OUTREACH: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered as Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)	Yuliya Linhares	Poster Presentation #4673	705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III	Monday, December 12, 6:00 – 8:00 PM
*Multiple Myeloma*
Alnuctamab (BMS-986349; CC-93269), a B-cell Maturation Antigen (BCMA) x CD3 2+1 T cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study	Sandy W. Wong	Oral Presentation #162	653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Bispecific Monoclonal Antibodies in Myeloma	Saturday, December 10, 1:15 PM
KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-risk Multiple Myeloma Patients with Early Relapse After Frontline Autologous Stem Cell Transplantation	Saad Usmani	Oral Presentation #361	704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR T in Multiple Myeloma and T-cell Therapies After Allo-HCT	Saturday, December 10, 4:00 PM
Clinical Activity of BMS-986393 (CC-95266), a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients With Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results From a Phase 1, Multicenter, Open-Label Study	Susan Bal	Oral Presentation #364	704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR T in Multiple Myeloma and T-cell Therapies After Allo-HCT	Saturday, December 10, 4:45 PM
Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial	Sagar Lonial	Poster Presentation #1918	653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster I	Saturday, December 10, 5:30 – 7:30 PM
Results From the First Phase 1 Clinical Study of the B-cell Maturation Antigen (BCMA) NEX-T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)	Luciano Megala Costa	Oral Presentation #566	653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Novel Drugs and Optimized Approaches in Myeloma	Sunday, December 11, 12:15 PM
Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial	Paul Richardson	Oral Presentation #568	653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Novel Drugs and Optimized Approaches in Myeloma	Sunday, December 11, 12:45 PM
KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-risk Multiple Myeloma due to Inadequate Response to Frontline Autologous Stem Cell Transplantation	Madhav Dhodapkar	Poster Presentation #3314	704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II	Sunday, December 11, 6:00 – 8:00 PM
*Myelodysplastic Syndromes*
Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: an Evaluation of US Clinical Practice Utilization and Treatment Patterns	Sudipto Mukherjee	Oral Presentation #389	906. Outcomes Research—Myeloid Malignancies I	Saturday, December 10, 5:00 PM
Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study	Uwe Platzbecker	Poster Presentation #3098	637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster II	Sunday, December 11, 6:00 – 8:00 PM
Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial	Valeria Santini	Poster Presentation #1174	637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster I	Sunday, December 11, 5:30 – 7:30 PM
*Myelofibrosis*
Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial	Vikas Gupta	Poster Presentation #1711	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I	Saturday, December 10, 5:30 – 7:30 PM
BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study	Rosa Ayala	Poster Presentation #4346	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III	Monday, December 12, 6:00 – 8:00 PM

Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases

Related Topics and Keywords

Subscribe to our FREE newsletter and WEBINAR UPDATES